Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

Background: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. Objectives: The aim of this retrospective multicenter real-world cohort study was t...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Manon Falette-Puisieux, Jean-Charles Nault, Mohamed Bouattour, Marie Lequoy, Giuliana Amaddeo, Thomas Decaens, Frederic Di Fiore, Sylvain Manfredi, Philippe Merle, Aurore Baron, Christophe Locher, Anna Pellat, Romain Coriat
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2023-08-01
Serija:	Therapeutic Advances in Medical Oncology
Online dostop:	https://doi.org/10.1177/17588359231189425
Oznake:	Označite Brez oznak, prvi označite!